PubMed Health⌕ Search

Biomedical subjects

M Landwehr

Publications and source records attributed to M Landwehr.

2 recordsLinked to original sources

The neuron-specific Ca2+-binding protein caldendrin: gene structure, splice isoforms, and expression in the rat central nervous system.

Caldendrin is the founder member of a recently discovered family of calmodulin-like proteins, which are highly abundant in brain. In this study we examined the organization of the murine and human caldendrin gene as well as the expression pattern of transcripts for caldendrin and two novel splice variants. In addition the distribution of caldendrin in rat brain has been assessed by immunohistochemistry. Caldendrin is localized to the somatodendritic compartment of a subpopulation of mainly principal neurons in brain regions with a laminar organization and is present only at a subset of mature excitatory synapses. Caldendrin immunoreactivity (IR) is tightly associated with the cortical cytoskeleton, enriched in the postsynaptic density (PSD) fraction, and associates late during development with the synaptic cytomatrix. The expression is highly heterogenous within cortex, with highest levels of caldendrin IR in layer III of the piriform and layer II/III of the somatosensory cortex. The segregated cortical distribution to areas, which represent the most important primary sensory systems of the rodent brain, may reflect different requirements for dendritic Ca2+-signaling in these neurons. The presence of caldendrin in the PSD of distinct synapses may have important implications for Ca2+-modulated processes of synaptic plasticity.

Alternative Splicing↗

Application of Synovex-H in veal calves: steroid release and residues.

Four experiments were carried out with veal calves which were implanted subcutaneously with Synovex-H. Testosterone in blood plasma and also total oestrogens in plasma, urine and faeces during the trial and in liver, kidney and muscle after slaughter (62-75 days after implantation) were determined. Prepurification methods and radioimmunoassays for faeces and tissue samples were elaborated and validated. Variables between or within the trials were the sex, the dose (four pellets versus eight pellets; 25 mg testosterone propionate + 2.5 mg 17 beta-oestradiol-3-benzoate per pellet) and the implantation site (either on the base of the ear or on the middle of the pinna). Results from the blood plasma and the excreta showed that using four pellets implanted in the middle of the pinna guaranteed a continuous release in order that oestrogen levels were maximally doubled in comparison to controls. On the other hand, application of the same dose at the base of the ear was characterized by an accentuated burst during the first three days (10-fold elevation over controls). In plasma and excreta of male controls, higher oestrogen concentrations were measured as compared to the corresponding substrates of females. Comparing all groups, untreated males showed the highest testosterone levels. In all animals, residues of total oestrogens were of the same order of magnitude (kidney and liver 0.1-1.5 ng/g; muscle 0-32 pg/g) with somewhat higher means in the treated groups. Since all results are within the physiological scope, no risk for the consumer is visible after correct use of Synovex-H.

Anabolic Agents↗